BioCryst Pharmaceuticals | BCRX - Current Assets


BioCryst Pharmaceuticals reported $531.15M in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
BioCryst Pharmaceuticals USD 531.15M 46.47M Sep/2026
Chugai Pharma JPY 1.64T 65.29B Sep/2026
Daiichi Sankyo JPY 2.38T 150.33B Sep/2026
DBV Technologies USD 189.6M 12.3M Sep/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Gilead Sciences USD 16.55B 4.02B Sep/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
Glaxosmithkline GBP 17.9B 134M Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
Ionis Pharmaceuticals USD 2.49B 446.73M Jun/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Neurocrine Biosciences USD 2.01B 370.7M Sep/2026
Novavax USD 707.96M 63.14M Sep/2026
PTC Therapeutics USD 2.54B 79.58M Sep/2026
Regeneron Pharmaceuticals USD 20.8B 2.35B Sep/2026
Roche Holding CHF 35.44B 3.29B Jun/2026
Sarepta Therapeutics USD 2.27B 49.06M Sep/2026
Ultragenyx Pharmaceutical USD 544M 62M Sep/2026
Vertex Pharmaceuticals USD 11.69B 857.4M Sep/2026